## Supplemental Table 1. Adverse Events in HRAS-mutant salivary cancer patients treated with tipifarnib

Adverse Event	All grades (%) <sup>a</sup>	Grade 3-4 (%)
Hematologic		
Neutropenia	5 (38)	4 (31)
Anemia	4 (31)	3 (23)
Thrombocytopenia	2 (15)	1 (8)
Gastrointestinal		
Stomatitis	0	0
Nausea	5 (38)	1 (8)
Vomiting	2 (15)	0
Dyspepsia	1 (8)	0
Diarrhea	0	0
Genitourinary		
Elevated creatinine	2 (15)	2 (15)
Respiratory		
Pneumonitis	0	0

<sup>a</sup> reported based on CTCAE (Common Terminology Criteria for Adverse Events) version 4.0